The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Webcasts|March 18, 2020
Headspace Gas Ingress Testing for Container Closure Integrity
Author(s)LIGHTHOUSE
Imagine a blue dye test that uses a tracer gas in place of the dye. Headspace gas ingress testing is a robust detection method of critical leaks. Drug developers considering an upgrade to blue dye testing can learn more about this test method in this webcast. Live: Wednesday, Mar. 18, 2020 at 11:30am EDT | 8:30am PDT | 3:30pm GMT | 4:30pm CET On Demand: available after airing until Mar. 18, 2021. Register free: http://www.pharmtech.com/pt_w/closure
Register free:
Event Overview:
Are you revising your container closure integrity (CCI) testing strategy? Regulators are paying closer attention to the proper design of robust CCI studies. This webcast will introduce the headspace gas ingress testing approach, a robust detection method of critical leaks. This rapid, non-destructive, analytical measurement can be scientifically validated and is an upgrade to the blue dye test. Topics to be discussed include the following:
- Evolution in industry best practices and regulatory requirements for CCI testing
- Introduction to headspace gas ingress testing
- Advantages of the headspace gas ingress testing method compared with blue dye testing
- Method development and the use of positive controls
- Industry case studies
Key Learning Objectives:
- Receive an update on industry best practices for container closure integrity (CCI) testing
- Learn about headspace gas ingress testing and how it compares to blue dye testing
- Learn about method development and how to validate this CCI test method
Speaker: Derek Duncan, PhD, Director Product Line, LIGHTHOUSE
Time and date: Wednesday, Mar. 18, 2020 at 11:30am EDT | 8:30am PDT | 3:30pm GMT | 4:30pm CET
On demand available after airing until Mar. 18, 2021.
Sponsor: LIGHTHOUSE
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.